[{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet for Suspension","sponsorNew":"Lupin Ltd \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Natco Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Bosentan Hydrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Tracleer-Generic (bosentan) is an endothelin receptor antagonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.

                          Product Name : Tracleer-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Natco Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Tracleer (Bosentan) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Tracleer

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 03, 2024

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistanc...

                          Product Name : Bosentan-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 15, 2023

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 24, 2019

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Retinset

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Retinset

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 28, 2019

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Instituto Universitario de Oftalmobiología Aplicada

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          University Medical Center Groningen

                          Country arrow
                          Luxepack
                          Not Confirmed

                          University Medical Center Groningen

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Scleroderma, Systemic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 24, 2015

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Radboud University Medical Center

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Radboud University Medical Center

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 30, 2013

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Scleroderma, Systemic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 18, 2011

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Bosentan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Persistent Fetal Circulation Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 08, 2011

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Christoph Hehrlein

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Christoph Hehrlein

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Tracleer is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Raynaud Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 22, 2011

                          Lead Product(s) : Bosentan Hydrate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank